Veligrotug
| Clinical data | |
|---|---|
| Trade names | Lumvoa |
| Other names | AVE-1642, VRDN-001, veligrotug-vvze |
| AHFS/Drugs.com | Multum Consumer Information |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Insulin-like growth factor-1 receptor inhibitor |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6580H10160N1752O2038S40 |
| Molar mass | 147702.29 g·mol−1 |
Veligrotug, sold under the brand name Lumvoa, is a monoclonal antibody medication used for the treatment of thyroid eye disease.[1] It is an insulin-like growth factor-1 receptor inhibitor.[1][2] It is given via intravenous injection.[1]
Veligrotug was approved for medical use in the United States in June 2026.[3]
Medical uses
Veligrotug is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.[1]
Society and culture
Legal status
Veligrotug was approved for medical use in the United States in June 2026.[4]
Names
Veligrotug is the international nonproprietary name.[5]
Veligrotug is sold under the brand name Lumvoa.[6]
References
- 1 2 3 4 5 "Lumvoa- veligrotug injection". DailyMed. 29 June 2026. Retrieved 3 August 2026.
- ↑ Kaplan R, Zhao Y, Tsai J, Dickinson B, Swanson T, Foster K, et al. (December 2025). "Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease". mAbs. 17 (1) 2585616. doi:10.1080/19420862.2025.2585616. PMC 12629334. PMID 41250603.
- ↑ "Lumvoa (veligrotug-vvze) FDA Approval History". Drugs.com. 28 June 2026. Retrieved 1 July 2026.
- ↑ "Drugs@FDA: FDA-Approved Drugs". Food and Drug Administration (FDA). Retrieved 1 July 2026.
- ↑ World Health Organization (2023). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 90". WHO Drug Information. 37 (3). hdl:10665/373341.
- ↑ "Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease". Viridian Therapeutics. 26 June 2026. Retrieved 1 July 2026 – via Business Wire.
External links
- "Veligrotug ( Code - C79798 )". EVS Explore.
- Clinical trial number NCT05176639 for "A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) (THRIVE)" at ClinicalTrials.gov
- Clinical trial number NCT06021054 for "An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) (THRIVE-2)" at ClinicalTrials.gov